Table 5.
Trials assessing anti-angiogenic as neoadjuvant treatment.
| Ref. | Pathology | Investigational treatment | n. | Clinical outcome | Pathological response |
|---|---|---|---|---|---|
| Systemic treatments | |||||
| Navid et al. Int J Cancer 2017 (62) | Operable osteosarcoma | Bevacizumab, methotrexate, doxorubicin and cisplatin | 31 | 4-year EFS = 57% 4-year OS = 83% |
Good pathological response: 28% |
| Ronellenfitsch et al. Ann Surg Oncol 2019 (63) | Localized soft tissue sarcoma | Pazopanib | 21 | No metabolic response | No patient with complete pathological response |
| Munhoz et al. Oncologist 2015 (64) | Localized soft tissue sarcoma | Gemcitabine, docetaxel, pazopanib | 5 | No objective response | 1 complete pathological response |
| Verschraegen et al. Ann Oncol 2012 (19) | Localized soft tissue sarcoma | Bevacizumab + Gemcitabine + Docetaxel | 15 | ORR: 6/15 = 40% 2y-OS rate = 69% |
2 complete pathological responses |
| Concurrent radiotherapy and tyrosine kinase inhibitor | |||||
| Hass et al. Acta Oncologica 2015 (65) | Localized soft tissue sarcoma | Pazopanib | 12 | No objective response 0/12 DLT |
Pathological response: 4/10 |
| Canter et al. Ann Surg Oncol 2014 (66) | Localized soft tissue sarcoma | Sorafenib | 8 | 1 objective response 2/8 DLT |
Pathological response : 3/8 |
| Meyer et al. CCR 2013 (67) | Localized soft tissue sarcoma | Sorafenib | 18 | - 3/18 DLT |
Pathological response: 7/16 |
| Jakob et al. Radioth Oncol (60) | Localized soft tissue sarcoma | Sunitinib | 9 | 1 objective response 1/9 DLT |
Pathological response: 3/9 |
| Lewin et al. BJC 2014 (59) | Localized soft tissue sarcoma | Sunitinib | 9 | 1 objective response 4/9 DLT |
– |
EFS, event-free survival; OS, overall survival; ORR, objective response rate according to RECIST; DLT, dose-limiting toxicities.